Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 7;9(7):e70171.
doi: 10.1002/hem3.70171. eCollection 2025 Jul.

Circulating tumor-associated and neoantigen-specific endogenous T cells in children treated for B-acute lymphoblastic leukemia

Eliane Huwiler  1 , Anne-Christine Thierry  2   3   4 , Justine Michaux  3 , Huisong Pak  3 , Florian Huber  3 , Caroline Arber  3   4 , Michal Bassani-Sternberg  2   3 , Alexandre Harari  3   4 , Francesco Ceppi  1
Affiliations

Circulating tumor-associated and neoantigen-specific endogenous T cells in children treated for B-acute lymphoblastic leukemia

Eliane Huwiler et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicting interest with the submission of this article.

Figures

Figure 1
Figure 1
Endogenous immune response against tumor‐expressing tumor‐associated antigens (TAAs) after remission. (A) % of bone marrow (BM) T cells responding to each identified TAA normalized to maximal response (Staphylococcal enterotoxin B [SEB]) at diagnosis (left panel) and quantification of tested TAAs versus immunogenic TAAs (right panel) for one patient (ISHOP07). (B) % of peripheral blood mononuclear cells (PBMCs) responding to each identified TAA normalized to maximal response (SEB), after remission (left panel) and quantification of tested TAAs versus immunogenic TAAs (right panel) for all patients. (C) Lymphocytic response rate against tested TAAs per patient. (D) Cumulative cytokine responses to all TAAs in an individual patient.
Figure 2
Figure 2
Endogenous immune response against predicted neoantigens after remission. (A) % of peripheral blood mononuclear cells (PBMCs) responding to each tested neoantigen normalized to maximal response (Staphylococcal enterotoxin B [SEB]) (left panel) and quantification of tested neoantigens versus immunogenic neoantigens (right panel) for two patients after remission (V3). For ISHOP13, due to limited sample size, peptides were tested as pools rather than individually. (B) For ISHOP14, % of PBMCs responding to each tested neoantigen normalized to maximal response (SEB) following two rounds of in vitro stimulation at follow‐up timepoint 2 years after initial treatment (left panel) and quantification of tested neoantigens versus immunogenic neoantigens (right panel). (C) Lymphocytic response rate against tested neoantigens per patient. (D) Cumulative cytokine responses to all neoantigens in individual patients. (E) For ISHOP 14, cytokine production of CD4+ T cells rechallenge with L‐8 peptide (left panel) and functional profile of L‐8‐specific CD4+ T cells (right panel). IFN, interferon; TNF, tumor necrosis factor.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Filbin M, Monje M. Developmental origins and emerging therapeutic opportunities for childhood cancer. Nat Med. 2019;25(3):367‐376. - PMC - PubMed
    1. Majzner RG, Heitzeneder S, Mackall CL. Harnessing the immunotherapy revolution for the treatment of childhood cancers. Cancer Cell. 2017;31(4):476‐485. - PubMed
    1. Ceppi F, Beck‐Popovic M, Bourquin JP, Renella R. Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot. Eur J Pediatr. 2017;176(9):1163‐1172. - PubMed
    1. DiNofia AM, Maude SL. Chimeric antigen receptor T‐cell therapy clinical results in pediatric and young adult B‐ALL. HemaSphere. 2019;3(4):e279. - PMC - PubMed
    1. Gupta S, Rau RE, Kairalla JA, et al. Blinatumomab in standard‐risk B‐cell acute lymphoblastic leukemia in children. N Engl J Med. 2025;392(9):875‐891. - PMC - PubMed

LinkOut - more resources